Research graph
References from MRD negativity by PBMCs and ctDNA confirms deep and durable responses after epcoritamab monotherapy in R/R FL. Local targets link to admitted publications; unresolved targets remain external evidence.
Follicular lymphoma
10.1038/s41572-019-0132-x · 2019 · External reference
Follicular lymphoma in the 5th edition of the WHO-classification of haematolymphoid neoplasms—updated classification and new biological data
10.3390/cancers15030785 · 2023 · External reference
Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study
10.3324/haematol.2022.281421 · 2023 · External reference
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups
10.1038/s41408-020-00340-z · 2020 · External reference
Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials
10.1182/bloodadvances.2020002724 · 2021 · External reference
Follicular lymphoma international prognostic index
10.1182/blood-2003-12-4434 · 2004 · External reference
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
10.1182/blood.2020010263 · 2022 · External reference
Upfront identification of high-risk follicular lymphoma
10.1002/hon.2852 · 2021 · External reference
Comparative analysis of bispecific antibodies and CAR T-cell therapy in follicular lymphoma
10.1111/ejh.14335 · 2025 · External reference
Thinking “outside the germinal center”: re-educating T cells to combat follicular lymphoma
10.1016/j.blre.2023.101099 · 2023 · External reference
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
10.1016/j.ebiom.2019.102625 · 2020 · External reference
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
10.1016/s2352-3026(24)00166-2 · 2024 · External reference
Unresolved reference
External reference
Unresolved reference
2024 · External reference
Unresolved reference
2024 · External reference
Unresolved reference
2023 · External reference
Unresolved reference
External reference
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
10.1016/s0140-6736(25)02360-8 · 2026 · External reference
Minimal residual disease in follicular lymphoma
2021 · External reference
End points and outcomes in follicular lymphoma: what should we measure, how, and why?
10.1182/blood.2024026978 · 2025 · External reference
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma
10.1182/blood.v99.3.856 · 2002 · External reference
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program
10.1182/blood-2013-06-507319 · 2013 · External reference
MRD monitoring by euroclonality IGH based NGS approach predicts outcome in follicular lymphoma patients lacking a conventional BCL2::IGH marker: a substudy from the Fondazione Italiana Linfomi (FIL) FOLL12 trial [abstract]
10.1182/blood-2023-181813 · 2023 · External reference
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
10.1200/jco.2013.54.8800 · 2014 · External reference
A prognostic model for relapse in patients with follicular lymphoma treated with immunochemotherapy using baseline metabolic tumor volume and interim PET
2020 · External reference
Minimal residual disease (MRD) status by peripheral blood mononuclear cells (PBMCs) and circulating tumor DNA (ctDNA) demonstrates rapid, deep, and sustained response in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL) treated with subcutaneous (SC) epcoritamab monotherapy in the pivotal phase 1/2 EPCORE™ NHL-1 trial [abstract]
10.1158/1538-7445.am2024-5071 · 2024 · External reference
Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma
10.1111/cas.15996 · 2023 · External reference
Long-term follow-up of patients with follicular lymphoma using next generation sequencing to detect minimal residual disease
10.1016/j.clml.2024.04.009 · 2024 · External reference
The minimal residual disease in non-Hodgkin's lymphomas: from the laboratory to the clinical practice
10.3389/fonc.2019.00528 · 2019 · External reference
Monitoring of circulating tumor DNA predicts response to treatment and early progression in follicular lymphoma: results of a prospective pilot study
10.1158/1078-0432.ccr-22-1654 · 2023 · External reference
Analytical evaluation of the clonoSEQ assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma
10.1186/s12885-020-07077-9 · 2020 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2021 · External reference
Minimal residual disease (MRD), pharmacokinetic (PK), and pharmacodynamic (PD) assessment of epcoritamab 2- vs 3-step step-up dosing in patients with relapsed/refractory follicular lymphoma (R/R FL) [abstract]
2024 · External reference
Minimal residual disease status predicts outcome in patients with previously untreated follicular lymphoma: a prospective analysis of the phase III GALLIUM study
10.1200/jco.23.00838 · 2024 · External reference
Minimal residual disease (MRD) status predicts outcomes in patients with follicular lymphoma (FL) treated with chemo-immunotherapy on SWOG S0016 [abstract]
10.1182/blood-2023-179612 · 2023 · External reference
Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma
10.1200/jco.2018.78.5246 · 2018 · External reference
Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease
10.1111/bjh.19458 · 2024 · External reference
Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT
10.1038/s41375-022-01803-x · 2023 · External reference
Minimal residual disease detection in lymphoma: methods, procedures and clinical significance
10.3389/fimmu.2024.1430070 · 2024 · External reference
